Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Stoke Therapeutics is a clinical-stage biotechnology company developing antisense oligonucleotide (ASO) therapies targeting severe genetic diseases caused by haploinsufficiency. The company's lead program, STK-001, is in Phase 3 development for Dravet syndrome, a rare pediatric epilepsy affecting approximately 1 in 15,700 births. With no current revenue and a $1.8B market cap, the stock trades on clinical trial milestones, regulatory pathway clarity, and partnership potential for its TANGO (Targeted Augmentation of Nuclear Gene Output) platform.
Stoke develops proprietary ASO therapies that upregulate protein production from the healthy gene copy in haploinsufficiency disorders. The TANGO platform targets pre-mRNA to increase functional protein levels without gene editing. Revenue model depends on successful Phase 3 completion of STK-001 for Dravet syndrome, followed by regulatory approval and commercial launch in orphan drug markets with pricing power ($200K-$400K annually typical for rare pediatric neurological disorders). The company will monetize through direct commercialization in the US and potential ex-US partnerships. Current burn rate of approximately $100M annually suggests 3-4 years of runway based on $653M cash position (estimated from balance sheet metrics). Pricing power derives from orphan drug exclusivity, lack of disease-modifying alternatives for Dravet syndrome, and high unmet medical need in severe pediatric epilepsy.
STK-001 Phase 3 clinical trial data readouts for Dravet syndrome (efficacy on seizure frequency reduction, safety profile)
FDA regulatory interactions and guidance on approval pathway, including potential accelerated approval discussions
Pipeline expansion announcements for additional haploinsufficiency targets (autosomal dominant disorders)
Strategic partnerships or licensing deals that validate TANGO platform technology and provide non-dilutive funding
Cash runway updates and equity financing announcements (dilution concerns given negative operating cash flow)
Binary clinical trial risk: STK-001 Phase 3 failure would eliminate 80%+ of company value given single lead asset concentration. Dravet syndrome trials face challenges with heterogeneous patient populations and placebo response variability.
Regulatory pathway uncertainty for novel mechanism (TANGO platform untested in approved therapies). FDA may require additional safety data or longer-term follow-up given pediatric population and chronic dosing requirements.
Reimbursement risk in rare disease markets: payers increasingly scrutinizing ultra-orphan drug pricing despite small patient populations (estimated 5,000-8,000 Dravet patients in US).
Epidiolex (cannabidiol) and other anti-epileptic drugs provide symptomatic management, though not disease-modifying. Gene therapy approaches from competitors (Encoded Therapeutics, Neurogene) target underlying SCN1A mutations with potentially curative intent.
Platform risk: antisense oligonucleotide space crowded with Ionis Pharmaceuticals, Sarepta, and others possessing deeper manufacturing expertise and established regulatory track records. TANGO differentiation depends on demonstrating superior efficacy/safety versus alternative ASO designs.
Cash burn of $100M+ annually with no revenue requires equity financing within 24-36 months absent partnership deals. Dilution risk significant if capital raised at unfavorable valuations during biotech sector downturns.
Minimal debt provides flexibility but also indicates limited access to non-dilutive financing. Venture debt typically requires clinical milestones as covenants.
low - Pre-revenue rare disease biotech with value driven entirely by clinical and regulatory milestones, not economic cycles. Dravet syndrome patients require treatment regardless of GDP growth. However, macro conditions affect: (1) ability to raise capital in risk-off environments, (2) acquisition appetite from large pharma partners, and (3) discount rates applied to future cash flows in DCF models. The 220% one-year return suggests momentum-driven trading amplified by biotech sector rotation.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (first potential revenue 2027-2028 post-approval). Clinical-stage biotechs are long-duration assets similar to zero-coupon bonds. Higher rates also increase financing costs for future capital raises, though current 6.53x current ratio and minimal debt (0.01 D/E) provide near-term insulation. The 10-year Treasury yield directly affects comparable biotech sector multiples and risk appetite for speculative growth stocks.
Minimal direct credit exposure given negligible debt and strong balance sheet liquidity. However, tighter credit conditions reduce M&A activity from strategic acquirers (large pharma) and limit venture debt availability for extending runway. High-yield credit spreads serve as proxy for risk appetite in speculative biotech investing.
growth/momentum - Attracts speculative biotech investors focused on binary clinical catalysts and high-risk/high-reward profiles. The 220% one-year return and 70% six-month return indicate momentum-driven trading. Pre-revenue clinical-stage assets appeal to investors willing to underwrite 3-5 year timelines to commercialization with potential 5-10x returns on successful approval, but total loss on failure. Not suitable for value or income investors given negative cash flows and no dividend. Hedge funds and biotech-focused funds dominate ownership.
high - Clinical-stage biotech with single lead asset exhibits extreme volatility around data readouts, regulatory announcements, and sector rotation. Estimated beta >1.5 given small-cap biotech characteristics. Stock can move 30-50% on clinical trial results or FDA guidance. Low float and institutional concentration amplify price swings. Recent 15% three-month return modest compared to six-month/one-year suggests consolidation after major rally, likely following positive clinical update or partnership announcement in 2025.
